Verona Pharma PLC ADR (VRNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Verona Pharma PLC ADR (VRNA) has a cash flow conversion efficiency ratio of 0.110x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.56 Million) by net assets ($278.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Verona Pharma PLC ADR to measure how many days the company can operate on defensive assets alone.
Verona Pharma PLC ADR - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Verona Pharma PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Verona Pharma PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verona Pharma PLC ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Korean Air Lines Co
KO:003490
|
0.118x |
|
Andritz AG
VI:ANDR
|
0.044x |
|
Silicon Motion Technology Corporation
F:S9M
|
-0.034x |
|
Tingyi (Cayman Islands) Holding Corp
F:TYG
|
0.077x |
|
Next Vision Stabilized Systems
TA:NXSN
|
0.112x |
|
BARRY CALLEBA. ADR 1/100
F:BCLM
|
N/A |
|
Applied Digital Corporation
NASDAQ:APLD
|
0.038x |
|
The Swatch Group AG
F:UHRA
|
0.012x |
Annual Cash Flow Conversion Efficiency for Verona Pharma PLC ADR (2005–2024)
The table below shows the annual cash flow conversion efficiency of Verona Pharma PLC ADR from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see Verona Pharma PLC ADR market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $204.56 Million | $-122.20 Million | -0.597x | -196.53% |
| 2023-12-31 | $249.28 Million | $-50.22 Million | -0.201x | +22.44% |
| 2022-12-31 | $230.47 Million | $-59.86 Million | -0.260x | -15.61% |
| 2021-12-31 | $148.00 Million | $-33.25 Million | -0.225x | +7.86% |
| 2020-12-31 | $184.85 Million | $-45.08 Million | -0.244x | +75.58% |
| 2019-12-31 | $44.40 Million | $-44.34 Million | -0.999x | -247.03% |
| 2018-12-31 | $79.86 Million | $-22.98 Million | -0.288x | -11.07% |
| 2017-12-31 | $107.95 Million | $-27.97 Million | -0.259x | -59.81% |
| 2016-12-31 | $42.53 Million | $-6.89 Million | -0.162x | +85.74% |
| 2015-12-31 | $8.28 Million | $-9.41 Million | -1.137x | -304.82% |
| 2014-12-31 | $19.62 Million | $-5.51 Million | -0.281x | +71.73% |
| 2013-12-31 | $3.41 Million | $-3.39 Million | -0.993x | -2.41% |
| 2012-12-31 | $4.21 Million | $-4.08 Million | -0.970x | -149.67% |
| 2011-12-31 | $6.29 Million | $-2.44 Million | -0.389x | +19.22% |
| 2010-12-31 | $5.33 Million | $-2.56 Million | -0.481x | -33.08% |
| 2009-12-31 | $7.25 Million | $-2.62 Million | -0.361x | -6.93% |
| 2008-12-31 | $5.85 Million | $-1.98 Million | -0.338x | +18.99% |
| 2007-12-31 | $5.73 Million | $-2.39 Million | -0.417x | -363.37% |
| 2006-12-31 | $7.64 Million | $-687.68K | -0.090x | -4507.76% |
| 2005-12-31 | $1.68 Million | $3.44K | 0.002x | -- |
About Verona Pharma PLC ADR
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more